This post is from a suggested group
The Explosive Growth of the Transcatheter Aortic Valve Replacement (TAVR) Market: Expanding Indications, Device Innovation, and Competition with Surgical Aortic Valve Replacement (SAVR)
The Transcatheter Aortic Valve Replacement (TAVR) market has been an undisputed revolutionary force in cardiology over the last decade, transitioning from a high-risk patient procedure to a viable option for intermediate and even low-risk patients, demanding a focused discussion on its clinical and economic impact. The exponential market growth is largely fueled by overwhelming clinical trial evidence demonstrating non-inferiority, and often superiority, of TAVR outcomes compared to traditional Surgical Aortic Valve Replacement (SAVR) in increasingly younger and healthier patient populations. Technological advances in device design, including smaller delivery systems, improved valve sealing mechanisms to minimize paravalvular leak (PVL), and features that enable accurate positioning, have been pivotal in expanding its applicability. The discussion should center on the debate between TAVR and SAVR for low-risk patients, a major…